礼来RET抑制剂和阿斯利康PD-L1抑制剂临床结果亮眼(3)

2019-11-28  未知 admin

Imfinzi组合疗法在其它疗效终点上也表现出益处：12个月无进展生存率（PFS）为17.5%，化疗对照组为4.7%。患者的总缓解率（ORR）达到67.9%，化疗对照组为57.6%。22.7%的患者的缓解持续时间（DOR）达到12个月，化疗对照组为6.3%。此外，Imfinzi组合疗法的安全性与前期试验一致，没有发现新的安全性问题。

▲CASPIAN试验疗效终点详细结果（图片来源：参考资料[4]）

“SCLC是一种极具侵袭性的疾病。我们很高兴能够看到超过三分之一的SCLC患者在接受Imfinzi的联合治疗后，总生存期超过了18个月，”阿斯利康肿瘤学研发执行副总裁José Baselga博士说：“这一结果为医生提供了将Imfinzi与顺铂或卡铂化疗相结合的一种新的治疗选择。我们期待与监管机构合作，尽快将Imfinzi带给世界各地的SCLC患者。“

参考资料：

[1] Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer. Retrieved September 9, 2019, from https://investor.lilly.com/news-releases/news-release-details/lilly-announces-positive-results-selpercatinib-loxo-292

[2] Lilly Oncology Update at World Lung. Retrieved September 9, 2019, from https://investor.lilly.com/static-files/71602f34-5643-4c02-b50a-0af6a2733806

[3] Pralsetinib (BLU-667) demonstrates robust activity in RET-fusion-driven intracranial tumor models. https://www.blueprintmedicines.com/wp-content/uploads/2019/09/Blueprint-Medicines-IASLC-2019-Pralsetinib-BLU-667-Poster.pdf

[4] Imfinzi is first immunotherapy to show both significant survival benefit and improved, durable responses in extensive-stage small cell lung cancer，Retrieved September 09, 2019, from https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2019/rns1.html

▽关注【药明康德】微信公众号